Makers of brand-name drugs struck 40 patent settlemnts last year involving 31 drugs, up from 28 in 2011, according to the Federal Trade Commission. "Until this issue is resolved, we will all suffer the consequences of delayed generic entry -- higher prices for consumers, businesses, and the U.S. taxpayer," said FTC chairman Jon Leibowitz.

Related Summaries